Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung function ...

After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

Novel allogeneic CAR-T therapy demonstrates durable remission and immune-reset mechanism in systemic lupus erythematosus ...

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...

The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results from ...